Science & Medicine

MET-Amplified Lung Cancer: A New Target for XALKORI?

GRACEcast Lung Cancer Video by cancerGRACE - H. Jack West, MD

Jul 3, 201407:18Science & Medicine

Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.

About This Episode

MET-Amplified Lung Cancer: A New Target for XALKORI? is an episode from GRACEcast Lung Cancer Video by cancerGRACE - H. Jack West, MD. Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that i...

Podcast

This episode belongs to GRACEcast Lung Cancer Video.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Jul 3, 2014, 07:18 long, audio available.

MET-Amplified Lung Cancer: A New Target for XALKORI?

About This Episode

Related Episodes